Grants>Dementia

Alzheimer's Drug Discovery Foundation Young Investigator Scholarships for the 14th International Conference on Alzheimer's  Drug Discovery

Ten ADDF Young Investigator Scholarships will be presented.  Each of these 10 scholarships provides:

A single registration to attend the conference

Opportunity to present a poster at the conference

Name recognition in the program and on the conference website    

Scholarship recipients are expected to attend the 14th International Conference on Alzheimer's Drug Discovery to receive the award. 

ELIGIBILITY REQUIREMENTS

The applicant must be a graduate student or a postdoctoral fellow. Postdoctoral applicants should have no more than four years of postdoctoral training including postdoctoral training at other institutions.  Physician-scientists are eligible to apply.  The program has no geographic restrictions.  Women and minorities are strongly encouraged to apply.

DEADLINE

All applications must be submitted by July 19, 2013.  Winners will be announced via email. 

APPLICATION

The following materials must be submitted for consideration by the ADDF’s Young Investigator Scholarship Review Committee:

Application Form (sumbitted online)

Current curriculum vitae that includes a list of publications (by email to sclassen@alzdiscovery.org)

Request for Proposals: Creative Computational Approaches to Accelerate Drug Discovery for the Treatment and Prevention of Dementia

Current methods of drug discovery have had limited success at predicting clinical efficacy of investigational therapies in patients with Alzheimer’s disease and other age-related dementias.

Computational modeling, systems biology and pharmacology, and translational bioinformatics represent
a tremendous yet relatively under-developed opportunity to accelerate and improve this process particularly for dementias.

The Alzheimer’s Drug Discovery Foundation (ADDF) program on Aging & Alzheimer’s Disease Prevention is requesting proposals for innovative computational approaches to map disease and predict the efficacy of drugs to treat and prevent dementia. A variety of approaches and outcomes will be considered.

Priority will be given to interdisciplinary teams composed of computational and biology/disease experts, and to proposals that use and perhaps develop open-access databases of biological and clinical data.

The winning submission(s) will present the most scientifically compelling, novel, and viable program to accelerate drug discovery.

Funding Opportunity #1.

Novel computational approaches to modeling drug efficacy on a key therapeutic target for Alzheimer’s disease.
Quantitative systems pharmacology and other network modeling approaches are of interest, as well as translational bioinformatics approaches to rational drug repurposing and rational combinatorial therapies.

Priority will be given to targets other than beta-amyloid and acetylcholinesterase, including but not limited to neuroinflammation, mitochondrial function, insulin sensitivity, cholesterol and ApoE, and the neurovascular
unit.

Some applications may benefit from the use of the databases including but not limited to:

- The Gene Expression Omnibus (GEO) open-access database of genomics data and ProfileChaser, a related web server

-Life Sciences databases.

Funding Opportunity #2.

Novel computational approaches to model disease risk and progression based on risk factors. Research increasingly indicates that Alzheimer’s is a multi-factorial disease that can develop along different trajectories with multiple risk factors such as genotype, comorbidities, dietary and environmental factors.

Some applications may benefit from the use of open-access databases of epidemiological data
including but not limited to:

- The National Alzheimer’s Coordinating Center (NACC) (http://www.alz.washington.edu),

-The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (http://adni.loni.ucla.edu/data-samples/access
-data/),

- The C-Path online Data Repository (CODR) for Alzheimer’s Disease (http://www.c-path.org/CAMDcodr.cfm).

Mechanism(s) of support:

Up to $150,000 in funding is available for each grant for one-year duration, with the possibility of follow-
on funding for computational or experimental research.

Review Process:

The deadline date for applications is September 5, 2013.

Submission of a Letter of Intent (LOI) is required prior to August 22, 2013.

Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee. The award winner (s) will be publicly announced in Spring 2014.

Application Procedure:

All letters of intent and applications must be submitted electronically at www.alzdiscovery.org. Detailed application instructions are available on the website.

Request for Proposals: Accelerating Drug Discovery for Frontotemporal Dementias

Research investigating the pathologic mechanisms of neurodegeneration in frontotemporal dementia (FTD) and related disorders is advancing, creating new potential targets for drug discovery. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for  frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP).

Priority areas for this program include:

• Development of biomarkers to accelerate drug development and early diagnosis

• Innovative pilot clinical trials

• Target validation studies

• Development and testing of novel high throughput screening assays

• Medicinal chemistry on lead compounds

• Identification and in vitro testing of potentially disease modifying lead compounds

• ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds

• Testing of lead compounds in a relevant animal model for preclinical proof of concept

Please note: this funding will not support applications for basic research.

Mechanism (s) of support:

ADDF/AFTD will provide grants for one-year duration (up to $150,000 each) with the possibility of follow-on funding.

Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program
-related investment.

The deadline date for applications is September 5, 2013.

Submission of a Letter of Intent (LOI) is required prior to August 22nd, 2013.

Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee, including
members of AFTD’s Medical Advisory Council.

Applications from biotechnology companies will also be reviewed by ADDF’s external Business Advisory Board.
Award winners will be publicly announced in Spring 2014.

APPLICATION PROCEDURE

All letters of intent and applications must be submitted electronically at www.alzdiscovery.org.

Rosalinde Gilbert Innovations in Alzheimer’s Disease Caregiving Legacy Awards

With continuing support from The Rosalinde and Arthur Gilbert Foundation, Family Caregiver Alliance (FCA) is pleased to oversee the annual Rosalinde Gilbert Innovations in Alzheimer's Disease Caregiving Legacy Awards program in its sixth year.

Three awards of $20,000 each will be awarded to nonprofit organizations, government agencies or universities responding to a community need with a program or project which focuses primarily on family/informal caregivers of adults with Alzheimer's disease and related dementias. Only agencies operating within the continental United States are eligible to apply. One award will be granted in each of these categories:

Creative Expression: This award will go to programs or projects that use imaginative and creative approaches in supporting persons with dementia or family/informal caregivers of persons with Alzheimer's disease and related dementias. Some examples are programs or projects using art, music, theatre, journaling, multimedia (e.g. film, documentary, radio) or other types of creative expression.

Diverse/Multicultural Communities: This award will go to programs or projects that provide services, support or other types of outreach to family/informal caregivers of persons with Alzheimer's disease or related dementias in diverse ethnic, age diversity, religion/spirituality, gender, rural, low income, and LGBT or other communities.

Policy and Advocacy: This award will go to programs or projects that advocate for systems change for the benefit of family/informal caregivers or care recipients with Alzheimer's disease or related dementias. These efforts could focus on legislation, executive or administrative changes, advocacy campaigns, or any other action to strengthen the public or private sector's recognition and support of family/informal caregivers.

Award Timeline

Applications are available, online only. The closing deadline for 2013 applications is 5 p.m. (Pacific Time), Friday, August 16, 2013. Award announcements will be made by late November 2013. Award recipients will be honored at the 2014 Annual Conference of the American Society on Aging (ASA). Participates will be invited to present information about their awarded program or project at the conference. Travel stipends will be available for the conference.

Eligibility and Submission Conditions

Nonprofit organizations, government agencies and universities responding to a community need with a program or project that focuses primarily on family/ informal caregivers of adults with Alzheimer's disease and related dementias are eligible to apply. Family or informal caregivers are unpaid caregivers. The term includes family members, friends, domestic partners and neighbors. Support for family/informal caregivers need not be the primary mission of the organization, agency or university.

Nonprofit applicants must submit proof of their 501(c) (3) status or other nonprofit status by attaching a copy of their nonprofit designation letter to their application. For-profit entities are not eligible to apply.

The nominated program or project has to have been active during the calendar year of 2012 and/or 2013. If the program or project involves a major culminating event, that event must have occurred prior to application deadline.

For the Policy & Advocacy and Creative Expression categories, program or project may be related to either family/informal caregivers or persons with dementia or both.

For the Diversity/Multicultural Communities category, program/project must be specific to family/informal caregivers of persons with Alzheimer's disease or related dementias.

The applicant or other designated program or project representatives must be willing to share information about their program with others, including a presentation at a national professional conference, and to write up additional information to appear on FCA's website and/or future publications. Award recipients may also be asked to provide information about how the award was used to further advance the mission of the organization, agency, or university.

Application must be received by the extended deadline of 5 p.m. (Pacific Time), on Friday, August 16, 2013.

Applicants must apply electronically using the designated online system.

Applicants must designate the category in which they would like to be considered. Applicants are competing only against others within their chosen category. If the judges feel that the applicant would be better suited for another category, they will contact the applicant directly.

Request for Proposals: Association for Frontotemporal Degeneration Pilot Grant

Maximum Award: $60,000 for one year

AFTD provides support for basic and clinical research in frontotemporal degeneration and related clinical conditions (frontotemporal dementia, primary progressive asphasia, progressive supranuclear palsy and corticobasal syndrome). This grant is designed to seed original projects, with the goal of generating preliminary data toward a larger grant application to the NIH or other public or private agencies concerned with this important medical and social problem.

Applications due: July 1, 2013

Award date: October 1, 2013

Grant period: November 1, 2013 – November 1, 2014